Molina Q1 2026

Key Takeaways

• Adjusted EPS $2.35 beats $2.17 consensus
• Marketplace MCR effectively 79.5% after risk adjustment removal
• Medicaid same-store membership attrition worsened to -6%
• No open-market buybacks in Q1, signaling cash allocation shift
• Investor Day slated May 8 to outline 2027‑2029 EPS path

Pulse Analysis

Molina Healthcare’s first‑quarter earnings underscore a pivotal turnaround for the insurer. After a $93 million impairment tied to the exit of its standalone Medicare Advantage Prescription Drug (MAPD) product, the company posted a solid $2.35 adjusted EPS and $1.1 billion in operating cash flow. Reserve development surged to $253 million, reflecting a favorable swing in medical cost estimates that bolstered profitability. While the headline Marketplace medical cost ratio (MCR) of 84% appears modest, analysts recognize that risk‑adjustment settlements and CMS fraud clawbacks inflate the figure by roughly 450 basis points, revealing an underlying 79.5% MCR that meets the company’s target range.

The Marketplace reset remains the centerpiece of Molina’s strategy. By slashing its ACA book from 655,000 to 305,000 members and raising premiums about 30%, the insurer trimmed unprofitable exposure and forced a healthier risk pool. Retention of 70% of the remaining members—who are willing to pay higher prices—suggests price elasticity is manageable. Seasonal dynamics favor Q1, as new enrollees have yet to fully utilize benefits, meaning the MCR is likely to drift higher later in the year. The upcoming June risk‑adjustment data will be a critical barometer for confirming the sustainability of the 79.5% ratio.

Looking ahead, the mixed signals warrant close monitoring. Medicaid same‑store attrition deepened to –6%, and the absence of open‑market buybacks indicates a shift in capital deployment priorities. Nonetheless, the stock rallied over 10% on the earnings beat, and Mizuho lifted its price target to $195. Management has deferred detailed guidance for 2027‑2029 to the May 8 Investor Day, where it will outline the path to normalized EPS in the mid‑to‑high $20s. Investors will weigh the strength of the Marketplace reset against the lingering Medicaid churn and capital‑allocation choices when assessing Molina’s long‑term valuation.